Loading...
•
Jun 30, 2022
ACADIA Q2 2022 Earnings Report
Reported a net sales increase of 17% year-over-year, NDA submitted for trofinetide for the treatment of Rett syndrome.
Key Takeaways
Acadia Pharmaceuticals reported a 17% increase in NUPLAZID net sales compared to Q2 2021. The company submitted an NDA for trofinetide for Rett syndrome and is well-positioned for long-term growth with a strong balance sheet and a focus on strategic business development.
NUPLAZID net sales increased by 17% year-over-year.
Submitted an NDA for trofinetide for the treatment of Rett syndrome.
Discontinued the development of ACP-044 and ACP-319.
Net loss was $34.0 million, or $0.21 per common share.
Revenue by Segment
Forward Guidance
Acadia has updated its 2022 financial guidance.
Positive Outlook
- NUPLAZID net sales guidance is updated to $510 to $540 million.
- GAAP R&D guidance is updated to $340 to $360 million, which includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance of $360 to $380 million is reiterated, which includes approximately $45 million of stock-based compensation expense.
- Developing pimavanserin in other neuropsychiatric conditions
- Advancing breakthroughs in neuroscience to elevate life
Challenges Ahead
- Uncertainty of future commercial sales and related items that would impact net sales during 2022
- Risks and uncertainties inherent in drug development, approval and commercialization
- Past results of clinical trials may not be indicative of future trial results
- Discontinuing the development of ACP-044 in acute and chronic pain
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...